Savicell™ has a first-in-class liquid ImmunoBiopsy™ platform designed for the early detection of disease. The platform identifies multiple diseases and may be used to track treatment effectiveness, including immunotherapy. The Company’s initial focus is on the multi-billion dollar, underserved cancer liquid biopsy market.

Metabolic changes in the immune system modulate cell fate and function, influencing immune response outcomes. These energy changes give the immune system the ability (effector function) to attack disease, including cancer. Diseases produce unique signatures in immune metabolic profiles that ImmunoBiopsy™ uses to distinguish between and within various ailments, such as cancers, autoimmune diseases, and infectious diseases. Savicell’s Liquid ImmunoBiopsy measures the energy changes of the immune system, which are disease-specific, and identifies the ailment.
​
Other liquid biopsy technologies in development evaluate secretions of cancer cells (looking for the criminal) and are more likely to detect late stage cancers. They have technical challenges for early-stage cancers and early cancer screening. In contrast, Liquid ImmunoBiopsy receives data directly from the immune system (interrogating the police). As an immune system test, it is inherently suited for early detection.